-
公开(公告)号:KR1020100093861A
公开(公告)日:2010-08-26
申请号:KR1020090012975
申请日:2009-02-17
Applicant: 서울대학교산학협력단
IPC: A61K31/4439 , A61P3/04 , A23L1/30 , A61K9/08
CPC classification number: A61K31/4439 , A23L33/10 , A61K9/0019 , A61K9/0053 , Y10S514/909
Abstract: PURPOSE: A composition containing metadoxine for preventing or treating obesity is provided to suppress lipid accumulation in cells without side effects and to prevent or treat obesity and complications thereof. CONSTITUTION: A pharmaceutical composition for preventing or treating obesity or complication thereof contains metadoxine(pyridoxol L-2-pyrrolidone-5-carboxylate), pharmaceutically acceptable salt thereof, solvate thereof, or hydrate as an active ingredient. The treatment of prevention of obesity or complications is suppression of PKA-CREB(protein kinase A-Cyclic AMP response element binding protein). The composition additionally contains other therapeutic agent for obesity together with metadoxine as active ingredients.
Abstract translation: 目的:提供含有用于预防或治疗肥胖症的替多他辛的组合物,以抑制细胞中的脂质积累,而不会产生副作用并预防或治疗肥胖及其并发症。 构成:用于预防或治疗肥胖症或并发症的药物组合物含有替莫多星(吡哆醇L-2-吡咯烷酮-5-羧酸酯),其药学上可接受的盐,溶剂合物或水合物作为活性成分。 预防肥胖或并发症的治疗是抑制PKA-CREB(蛋白激酶A-Cyclic AMP反应元件结合蛋白)。 该组合物另外含有其他治疗剂用于肥胖症以及替多他辛作为活性成分。
-
公开(公告)号:KR101068686B1
公开(公告)日:2011-09-29
申请号:KR1020090012975
申请日:2009-02-17
Applicant: 서울대학교산학협력단
IPC: A61K31/4439 , A61P3/04 , A23L1/30 , A61K9/08
Abstract: 본 발명은 메타독신 (pyridoxol L-2-pyrrolidone-5-carboxylate, metadoxine)을 유효성분으로 함유하는 비만 또는 이로 인한 합병증의 예방 또는 치료용 조성물 및 이를 사용하는 비만 또는 이로 인한 합병증의 에방 또는 치료에 관한 것이다.
메타독신, 비만증 치료, 약학 조성물
-